Association of Urinary Vitamin D-binding Protein and Megalin as Biomarkers for Diabetic Nephropathy in Type 2 Diabetes Mellitus in Qatari Patients by Sharif, E et al.
Volume 3   Issue 2 • 1000109J Diabetes Clin Prac, an open access journal
Open AccessResearch Article
Sharif et al., J Diabetes Clin Prac 2019, 3:2
Journal of 
Diabetes and Clinical PracticesJour
na
l o
f D
iab
etes a
nd Clinical Practice
10.6
have an increased rate of glucose intolerance in 17% of its population. 
Furthermore, in 2012, it was reported that the prevalence of Qatari 
T2DM patients was 16.7%, and by 2050, it is predicted to reach 24%, 
where most of T2DM are aged from 18 to 64 years old. Additionally, 
the prevalence of physical inactivity, obesity and active smoking were 
45.9%, 41.4% and 16.4% respectively [4]. Obesity is considered to be 
a key factor that affects two-thirds of the incidence of T2DM Qatari 
patients. Therefore, evaluating the future of T2DM in Qatar is crucial 
to be notified to control the prevalence of the disease by addressing 
new preventive methods, early detection of the disease and therapeutic 
interventions [4]. Moreover, it is a worldwide metabolic disease in 
which its prevalence is rising to more than one million new cases 
annually in the USA [1]. Additionally, in 2015, diabetes results in up to 
5 million deaths worldwide [5-13]. T2DM incidence differs significantly 
from one geographical area to another according to the variation of 
environmental, lifestyle and genetic risk factors. The prevalence of 
T2DM in adult patients is expected to rise in the next decades and to 
increase greatly in developing countries [14].
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Introduction
Diabetes mellitus
Diabetes mellitus (DM) is a chronic disorder that is characterized 
by multiple metabolic dysfunctions. This includes abnormal insulin 
secretion or insulin action or both of them, which can lead to 
hyperglycemia [1], and abnormal metabolism of carbohydrates, proteins 
and lipids [2]. DM has two types, Type 1 Diabetes Mellitus (T1DM), 
which is an insulin-dependent form of DM and Type 2 Diabetes Mellitus 
(T2DM), which is a non-insulin dependent form of DM. T2DM is more 
common, in which it occupies 90%-95% of the diabetic patients [3]. It 
affects people from both developing and developed countries that have 
an increased rate of diabetic-related mortality and morbidity. T2DM is 
a serious chronic disease that develops due to different hereditary and 
environmental factors, where most of its patients are obese or have a 
high percentage of body fat distributed among the abdominal region. 
Moreover, other modifiable risk factors could be included, such as 
the age and the absence of physical exercise [3]. The prevalence of the 
disease is still increasing; thus, it is important to introduce efficient 
strategies in order to prevent having any new cases and to enhance the 
early detection of the disease. Furthermore, this will prevent different 
complications of the disease, which includes kidney and heart diseases 
and retinopathy [3].
Epidemiology
DM is a leading cause of mortality and morbidity [1]. It is a common 
disease in Qatar. According to Hamad Medical Corporation (HMC) 
(2017), the prevalence of diabetes is 17% and 11-23% is at risk of having 
diabetes [2]. Moreover, Qatar is considered to be one of the countries that 
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Background: Nephropathy is a common complication of type 2 diabetes mellitus (T2DM). Previous studies 
revealed that T2DM patients with nephropathy have higher concentrations of urinary Vitamin D Binding Protein 
(VDBP) that carries vitamin D to the target tissues, and megalin that mediates endocytosis in the proximal tubule 
than those who are healthy. 
Methodology: 196 urine samples with their blood data were obtained from Qatar Biobank, of which 21 samples 
were measured for VDBP and megalin using enzyme-linked immunosorbent assay (ELISA). They were divided into 
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patients. However, the current study reveals that urinary VDBP and megalin levels were non-significantly elevated 
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Normal physiology of pancreas
Regulating the glucose level in the blood involves different organs, 
where the main organ is the pancreas, which controls this process by 
secreting either insulin or glucagon hormones that work against each 
other. Insulin is produced by the β-cells of the islets of Langerhans in 
the pancreas. It is secreted as a result of increased blood glucose level 
due to food intake in order to reduce the glucose level to the normal 
level, thus, it is called a hypoglycemic agent, noticing that it is the 
only hormone that performs this process. Insulin allows the glucose 
to enter the liver, muscle and adipose cells. Moreover, it controls the 
glucose level by increasing different processes that include glycolysis, 
glycogenesis (storing glucose in the liver by converting it into glycogen) 
and lipogenesis (converting glucose into fatty acids), and prohibiting 
glycogenolysis. Glucagon is produced by the β-cells of the islets of 
Langerhans in the pancreas. It is secreted as a result of decreased blood 
glucose level due to fasting and stress conditions in order to raise the 
glucose level to the normal level, thus, it is called a hyperglycemic agent. 
Glucagon stimulates glycogenolysis, which converts the glycogen that 
is stored in the liver into hepatic glucose and increases gluconeogenesis 
(synthesis of glucose from other sources rather than carbohydrates) 
[11].
Causes of T2DM
T2DM in the non-insulin dependent form of DM that is influenced 
by genetic factors. However, obesity, age, and lifestyle are independent 
risk factors that could accelerate the progression of T2DM in those who 
are genetically susceptible [11-13]. T2DM occurs as a result of insulin 
resistance and/or impaired pancreatic β-cell function that results in an 
insufficient insulin production. Consequently, the transportation of 
glucose into the liver, fat and muscle cells will reduce, which results 
in hyperglycemia [14]. Furthermore, it has been recognized that cell 
dysfunction is also involved in the etiology of T2DM. It results in the 
production of excessive levels of glucagon and hepatic glucose that also 
leads to fasting hyperglycemia [14].
Diagnosis of diabetes mellitus
DM could be diagnosed by testing random plasma glucose level, 
fasting plasma glucose level FPG; which is preferred over random plasma 
glucose level, Oral Glucose Tolerance Test OGTT; which determines 
the ability of the cells to absorb glucose by measuring glucose 2 hours 
after taking 75 g of glucose, and Hemoglobin A1c, HbA1c, which can be 
monitored over the period of two to three months of the diabetic patients 
(Table 1). Symptoms and signs, and the onset of the disease should be 
considered in order to differentiate between T1DM and T2DM, where 
T2DM is characterized by adult onset, polydipsia, polyuria, weight loss, 
hypertension, increased body mass index BMI: overweight 25 kg/m2, 
dyslipidemia, and signs of insulin resistance that can be confirmed by 
further tests [11], such as testing C-peptide, which is produced with 
each insulin molecule and has longer half-life time than insulin, thus, it 
is used to evaluate the function of pancreatic β-cells and to determine 
the insulin level in the blood [15].
FPG OGTT HbA1c
Normal 70-99 mg/dL <140  mg/dL <5.7%
Pre-diabetes 100-125 mg/dL 140-199 mg/dL 5.7%-6.4%
Diabetes (Need to be confirmed) ≥ 126 mg/dL ≥ 200  mg/dL ≥ 6.5%
Table 1: Shows different diagnostic tests of diabetes.  
Complications of diabetes mellitus
The hyperglycemia that result of T2DM can lead to macrovascular 
and microvascular complications. Macrovascular complications include 
hyperlipidemia, hypertension, coronary artery disease, heart attacks, 
strokes, and peripheral and cerebral vascular system diseases [16]. 
While microvascular complications include nephropathy, retinopathy 
and neuropathy. One of the most common complications of DM is 
Diabetic Nephropathy (DN), which will be discussed in detail [3].
Diabetic nephropathy
DN, which is also called Diabetic Kidney Disease (DKD) [17], is 
found in approximately 30-40% of diabetic patients. It is described by 
low Glomerular Filtration Rate (GFR) resulting in proteinuria. Also, it 
is a long-term complication that depends on the duration of diabetes 
being a chronic disease [5]. Unfortunately, controlling DM will not 
totally prevent the Chronic Kidney Disease (CKD) that leads to kidney 
failure at the advanced stage. Nephropathy is considered to be the most 
essential cause of chronic renal failure worldwide [18]. A study that was 
conducted by HMC between May 2001-2002 that included 225 Qatari 
diabetic patients showed that 40.9% of them have nephropathy [19]. Later 
between May 2011 to January 2013, another study included 1633 Qatari 
diabetic patients aged above 20 years, revealed that the prevalence of 
diabetic nephropathy was 12.4% [20]. Recently, in 2017, HMC revealed 
that 45.3% of 2000 diabetic patients were suffering from nephropathy 
[2]. Moving to the Gulf region, in Saudi Arabia, a study was conducted 
in 2004 about T2DM patients who were attending a primary health care 
centre in Abha city revealed that about 54.3% had proteinuria. Later in 
2013, a cross-sectional study that includes 54,670 Saudi T2DM patients 
who were members of Saudi National Diabetes Registry indicated that 
the prevalence of DN was 10.8%. In Kuwait, between June 2006 and 
May 2007, a study included El-Fahaheel primary health-care centre 
T2DM patients showed that the prevalence of macro-albuminuria was 
58.2%. Another study in Oman between 2010 to 2011 involved T2DM 
Omani patients revealed that 42.5% of them had proteinuria as a result 
of DN [21]. Moreover, about 24 million individuals in the United 
States have DM and approximately 180,000 of them are suffering 
from kidney failure due to diabetes and DKD. [18]. DN is a diabetic 
microvascular complication, which results from hyperglycemia that 
leads to oxidative stress, which accelerates the formation of Advanced 
Glycation End products (AGEs) in the circulation [22]. AGEs are the 
end products of Non-Enzymatic Glycation (NEG), in which sugars are 
bound to proteins. This will result in multiple cellular damages [23]. At 
the early stage of DN, AGEs cause glomerular endothelial dysfunction 
and alter the Extra Cellular Matrix (ECM) composition that leads to 
mesangium expansion and thickening of the Glomerular Basement 
Membrane (GBM) [22,23]. Furthermore, AGEs enhance angiotensin 
II activity [23], which causes vasoconstriction of efferent arteriole and 
vasodilation of afferent arteriole. This results in a high intraglomerular 
pressure that leads to hyperfiltration [24]. AGEs accumulation in 
the extracellular matrix components of kidney capillaries leads to 
podocytes injury [23], where podocytes have a role in maintaining 
glomerular permeability rate [22], in which they are considered to be 
as a barrier that prevents the plasma proteins to pass into the filtrate. 
Damaging podocytes includes their detachment and depletion, which 
results in increased vascular permeability of albumin, in which in the 
normal state, the glomerular filtrate is almost free from albumin [23]. 
This will lead to renal filtration dysfunction [22] that is characterized by 
low glomerular filtration rate. This usually indicates progressive DKD 
that is associated with the development of proteinuria that is described 
by micro-albuminuria and macro-albuminuria in diabetic patients [23]. 
Furthermore, this will overload the endocytosis of filtered AGEs in the 
epithelial cells of the proximal tubule that leads to cells toxicity and 
tubulo interstitial injury [9]. This is shown in Figure 1. DN is usually 
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effective therapy for glycemic control. Insulin can inhibit the secretion 
of the hepatic glucose and increase the utilization of postprandial 
glucose. Moreover, it can improve the insulin sensitivity of the cells and 
the secretory function of the β-cell by reducing the glucose level in the 
blood, hence, preventing the glucose toxicity [3].
Vitamin D binding protein
Vitamin D binding protein (VDBP) is also known as a group-specific 
component, which belongs to the Gc globulin family that albumin belongs 
to as well. VDBP is a 58 kDa glycosylated alpha-globulin, which is made 
up of 458 amino acids. It has different binding regions that enhance its 
functions, such as binding regions of vitamin D, fatty acid, and actin and 
cell surface [6]. VDBP is mainly secreted by the liver in quite constant 
rates during life. However, it has been observed that the concentration 
of VDBP increased under some condition like pregnancy, where the 
estrogen level is elevated and at day-time [6]. Other tissues/organs that 
can produce VDBP in low concentrations include abdominal fat, testis, 
and kidney. Also, it is expressed on the surface of immunocytes [26]. The 
main function of VDBP is to carry and transport the circulating vitamin 
D and its metabolites to the target tissues. In addition, the bioavailability 
of 1,25-dihydroxyvitamin D (1,25 (OH) 2D), the active form of vitamin 
D and its precursor 25-hydroxyvitamin D (25 (OH) D) is supported 
by VDBP. Furthermore, it has an important role in the biosynthesis of 
1,25 (OH) 2D in renal proximal tubules [7]. Indeed, VDBP offers less 
than 5% of its binding sites to be bound with vitamin D metabolites. 
Since VDBP has a stronger affinity for vitamin D metabolites than 
albumin, 85% to 95% of them are bound to VDBP. The rest of vitamin D 
metabolites (bioavailable) can bind to albumin or circulate in the blood 
(<5%) [6]. Moreover, the rest of VDBP are involved with other functions 
that are essential for the biological processes, which includes fatty acid 
transportation, actin scavenging, chemotaxis, osteoclasts stimulation 
and macrophages activation. It is also associated with T and B immune 
cells surfaces [1]. In addition, VDBP has an important role in immune 
response and inflammatory processes. Furthermore, bioinformatics 
analysis determined that Gc content play a role in apoptosis and epidermal 
growth factor receptor [26]. In the recent years, urinary VDBP (uVDBP) 
is considered to be as a novel biomarker of DN, where it enhances its 
detection in T2DM patients as discussed in which shows the previous 
studies that measure the uVDBP in T2DM.
diagnosed according to the presence of microalbuminuria in urine. This 
was useful in the early detection of the microvascular complications 
of the disease. Nevertheless, it is unable to predict DKD adequately, 
especially in young diabetic patients or those who are non-albuminuric. 
Further measurements were proposed to discover glomerular or/and 
tubular dysfunction [17]. Estimated Glomerular Filtration Rate (eGFR) 
is an equation that is used to calculate the GFR instead of direct testing 
of the urine sample. It is mainly based on serum creatinine, gender, age, 
and ethnicity, where it is used to reveal the glomerular function and 
the kidney status. Probably, blood testing of kidney function tests and 
urinalysis will be performed initially, where the abnormal results may 
give a hint about the general kidney status [11].
Treatment of T2DM
T2DM is mainly controlled by having a healthy lifestyle that is 
based on having diet and exercising to reduce and control obesity, 
glucose level, dyslipidemia, hypertension, and other complications [11-
14]. Some drugs could be used including metformin, sulfonylureas, 
thiazolidinediones, alpha-Glucosidase inhibitors, incretin-based 
therapies and insulin therapy. Metformin is an insulin sensitizer, which 
is the first oral therapeutic option in T2DM patients. It increases the 
insulin sensitivity of the cells and decreases the production of hepatic 
glucose, the absorption of glucose in the intestine, and the level of 
triglycerides and low-density lipoprotein (LDL) [25]. Sulfonylureas 
stimulate the production of endogenous insulin. However, it can cause 
hypoglycemia, especially in elderly patients. Thiazolidinedione is also 
an insulin sensitizer, which includes pioglitazone that well-tolerated 
in older patients and could be used by patients with renal impairment 
but not by patients with heart failure. Alpha-Glucosidase Inhibitors 
includes Acarbose, Miglitol and Voglibose are not commonly used to 
treat T2DM patients and should not be given to in cases of significant 
renal impairment. However, they are safe and effective, especially for 
postprandial hyperglycemia [14]. Incretins are intestinal secreted 
hormones that stimulate insulin production and inhibit postprandial 
glucagon production. Incretin-based therapies that include Glucagon-
Like Peptide 1 (GLP-1), is an ideal therapy of T2DM due to its good 
tolerability, efficacy, weight loss and low risk of causing hypoglycemia. 
It has a positive influence on central nervous, cardiovascular, 
inflammation, hepatic health and sleep system. Insulin therapy is an 
Figure 1: Shows the differences between normal glomerulus and diabetic glomerulus (A) Shows the normal structure of the glomerulus in healthy individuals. (B) 
Shows different structural abnormalities in diabetic patients as a result of diabetic nephropathy. It includes glomerular endothelial dysfunction, mesangium expansion, 
thickening of the glomerular basement membrane, vasoconstriction of efferent arteriole, vasodilation of afferent arteriole and podocytes detachment. In addition to 
proximal tubule epithelial cells injury. Where all of these structural abnormalities lead to low glomerular filtration rate and proteinuria.
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Megalin
Renal Proximal Tubule Epithelial Cells (PTEC) includes receptors 
that mediate endocytosis, which have a vital role in reabsorbing 
and metabolizing different substances including proteins and 
carrier-bound vitamins from glomerular filtrate. Any damage in the 
endocytosis process will lead to the passing of those substances into 
the urine, which results in proteinuria. This significantly indicates 
kidney and cardiovascular diseases [27,28]. Megalin is a 600 kDa 
glycoprotein with 4,655 amino acids that belongs to the LDL receptor 
family, in which it is encoded by LDL Related Protein 2 (LRP2) gene 
[10]. Megalin is mainly expressed in PTECs, specifically in its apical 
membranes, which is in contact with the lumen rather than the 
bloodstream. It is considered to be the most vital receptor in PTECs 
that is classified as a scavenger receptor, which mediates endocytosis 
of different ligands [29]. These ligands involve different binding 
proteins including Vitamin-Binding Proteins [29] (e.g. VDBP) [28], 
apolipoproteins, enzyme and enzyme inhibitors, hormones and 
hormone precursors, stress-and immune-response-related proteins, 
drugs and toxins [29]. Furthermore, megalin is present in small 
portions in lysosomes when assigned for degradation [10] and in 
different epithelial cells, such as glomerular podocytes, thyroid and 
parathyroid cells, type II pneumocytes and choroid plexus [29]. The 
renal proximal tubule shows a wide apical endocytic apparatus, which 
contains a network of molecules that collaborate with megalin to 
reabsorb the ligands from the glomerular filtrate, which explains the 
fact of human urine samples that are almost free from proteins under 
normal conditions. However, proteins are not the only vital substance 
that undergoes reabsorption, a variety of nutrients and molecules 
including vitamins with their binding proteins (e.g. VDBP) are also 
reabsorbed to be returned to the bloodstream [29]. Moreover, megalin 
has a role in taking up pathological and toxic molecules to PTECs or 
overloading endocytosis, which results in cellular damages that lead 
to kidney diseases [28-30]. In 2012, urinary megalin was considered 
to be as a novel biomarker of DN, in which it is a scavenger receptor 
that mediates the endocytosis of the AGEs and their degradation in 
PTECs [9-23] that leads to will lead to tubular injury [8] and shedding 
of megalin receptors through urine in diabetic patients [10]. Megalin 
enhances the detection of DN in T2DM patients as discussed in which 
shows the previous study that measures the urinary megalin in T2DM.
Association between VDBP and Megalin
The main function of VDBP is to carry the circulating vitamin D 
and its metabolites to the target tissues [7]. As a result of DN, VDBP 
secretion is increased in the urine. This will overload its reabsorption 
in the renal proximal tubules that is mediated by different receptors 
including megalin [8], which is a scavenger receptor that mediates the 
endocytosis in the PTECs of different ligands [9]. Endocytosis is an 
energy-consuming process, where in case of diabetes. It is overloaded by 
the increased secretion of uVDBP, which will lead to tubular injury [8] 
and shedding of megalin receptors through urine [10]. This association 
is shown in Figure 2.
Materials and Methods
One hundred ninety-six urine samples with their blood data 
were obtained from Qatar Biobank and stored at -80°C till further 
processing. Twenty-one samples were measured for VDBP and megalin 
using enzyme-linked immunosorbent assay (ELISA) (DVDBPOB for 
Human VDBP and LS-F11978 for Human LRP2/Megalin). This project 
was approved by Institutional Review Board (IRB) of Qatar Biobank 
(Approval number: Ex-2017-QBB-RES-ACC-0082-0029).
According to HMC, Modification of Diet in Renal Disease (MDRD) 
equation [31] was used to calculate the estimated glomerular filtration 
rate (eGFR) of all samples
Figure 2: Shows the association between VDBP and megalin. (A) Shows the Megalin mediated endocytosis of vitamin D and its carrier (VDBP) in PTECs of healthy 
individuals. In the lysosome, VDBP is degraded and return to blood circulation as amino acids with the vitamin D (B) In case of diabetes, VDBP secretion is increased in 
the urine, which will overload its reabsorption in the PTECs that is mediated by Megalin. This will lead to tubular injury (C) Shedding of Megalin receptors through urine.
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The samples were divided into three groups according to the level 
of the eGFR [11]; group 1 (control group with eGFR ≥ 90 mL/min/1.73 
m²), group 2 (T2DM patients with eGFR ≥ 90 mL/min/1.73 m²) and 
group 3; (T2DM patients with eGFR<90 mL/min/1.73 m²).
Study subjects
T2DM patients were included in the study. Pregnant ladies, smokers, 
and patients who are taking vitamin D supplements or any drugs (except 
diabetic medication), and having inflammations, tumors, or infections 
were excluded from the study. For the control group, individuals with 
normal lab results of HbA1c, C peptide protein, insulin, creatinine, 
urea, bilirubin, total protein, and albumin were used. Whereas patients 
who have diabetes, kidney and liver diseases, pregnancy, smoking, 
inflammations, urinary system disorders, tumors, infections and are 
taking any supplements or medications were excluded from the study. 
After obtaining the samples from Qatar Biobank, another exclusion 
criteria was performed. This is shown in Figure 3.
Determination of VDBP
The concentration of VDBP in urine samples was measured using 
human vitamin D BP Quantikine ELISA kit (catalog #: DVDBP0B; Lot #: 
P140502; R&D Systems, Minneapolis, MN, USA). First, the microplate 
was pre-coated with monoclonal antibodies specific for human VDBP. 
Standards and samples were pipetted in each well. In case VDBP is 
present, then it will bind to the immobilized antibody. Furthermore, 
washing step was performed to remove any unbound substances. After 
that, an enzyme-linked monoclonal antibody that is specific for VDBP 
(conjugate) was added. Later, washing was performed again to remove 
any unbound conjugate. Furthermore, the substrate was added, which 
contain color reagent A (stabilized hydrogen peroxide) and color 
reagent B (tetramethylbenzidine; stabilized chromogen) and the color 
was developed in proportion to the amount of VDBP bound in the 
initial step. Finally, stop solution was added to stop the reaction and 
the intensity of the color was measured using microplate reader at a 
wavelength 450 nm.
Determination of megalin
The concentration of megalin in urine samples was measured using 
human LRP2/megalin sandwich ELISA kit (catalog #: LS-F11978; Lot 
#: 115033; LifeSpan Biosciences, Seattle, WA, USA). First, the wells of 
the microtiter plate were pre-coated with a capture antibody that is 
specific to megalin. In each well, standards and samples were pipetted. 
If the megalin is present, then it will form a binding with the capture 
antibody. Furthermore, washing step was performed to remove any 
unbound substances. After that, detection reagent A was added, which 
is a biotin-conjugated detection antibody that binds to the captured 
antigen. Later, washing was performed again to remove any unbound 
conjugated antibody. Furthermore, detection reagent B was added, 
which is an Avidin-Horseradish Peroxidase (HRP) conjugate that 
binds to the conjugated antibody. Another washing step was performed 
again to remove any unbound Avidin-HRP conjugate. Additionally, 
the 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added. A 
color development was observed due to the reaction that had occurred 
between the TMB substrate and HRP enzyme, which was terminated 
by adding the stop solution (sulfuric acid). Finally, the color intensity 
of the microtiter plate was measured by using microplate reader at a 
wavelength of 450 nm.
Statistical analysis
Statistical analyses were performed using SPSS 24 software. Data 
presented the median and interquartile range (25-75%) for the non-
normally distributed continuous data. However, the mean and standard 
deviation were calculated for normally distributed continuous data. The 
comparison between groups for nonparametric values was analyzed by 
the Kruskal Wallis followed by post hock test. While for parametric 
values, ANOVA was used. Moreover, correlation analysis (Bivariate) 
was used to determine the correlation between eGFR, megalin, uVDBP, 
vitamin D and the duration of T2DM using Spearman correlation 
coefficient. All tests were two-tailed and a P-value of ≤ 0.05 was 
considered statistically significant.
Results
Clinical characteristics 
Table 2 demonstrates the study subjects that were divided into three 
groups according to eGFR. G1;which is a healthy control group with 
normal eGFR ≥ 90 ml/min/1.73 m2, G2; which presents T2DM patients 
with normal eGFR ≥ 90 ml/min/1.73 m2 and G3; which is T2DM 
patients with abnormal eGFR <90 ml/min/1.73 m2.
Correlations between different variables
The relationship between the main variables in this study was 
determined, which includes eGFR, megalin, uVDBP and the duration 
of T2DM. Megalin and uVDBP have non-significant negative linear 
relationships with eGFR (r=-0.315, P=0.165) and (r=-0.326, P=0.149) 
respectively. While the uVDBP has a non-significant positive linear 
relationship with duration of T2DM (r=0.054, P=0.861) and megalin 
Obtained from Qatar Biobank.  
40 samples were excluded: 
* Non-Qatari individuals. 
* Control group individuals with abnormal eGFR. 
* Individuals with 2 or more missing tests.  
 
* Were measured for urinary VDBP and megalin due to limited number of kits. 
* Divided into three groups.   
 
2
2
1 
196
156
Figure 3: Shows the exclusion criteria of Biobank samples.
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Comparison between the studied groups with respect to eGFR
Figure 4 shows the eGFR in G3 (86.4 (77.6-88.9)), which is 
significantly lower than G1 (97.1 (94.9-105.4), P=0.005) and G2 (100.8 
(95-105.6), P=0.004). However, there was no significant difference 
between G1 and G2 (P=1.00).
Comparison between the studied groups with respect to 
uVDBP
Figure 5 reveals the uVDBP concentrations in G3 (52.4 (32.8-61.4)), 
which is non-significantly higher than G1 (20.3 (16-22.1), P=0.198) and 
G2 (18.9 (14.2-48.4), P=0.198). Additionally, there was no significant 
difference when comparing G1 with G2 (P=0.198).
Variables G1 G2 G3 P-value (G1 & G2) P-value (G1 & G3) P-value (G2 & G3)
n=21 7 7 7    
Female 4 3 4 - - -
Male 3 4 3 - - -
Age 30 (26-46) 59 (50-63) 45 (37-59) - - -
eGFR (ml/min/1.73m2) 97.1 (94.9-105.4) 100.8 (95-105.6) 86.4 (77.6-88.9) 1 0.005* 0.004*
VDBP (ng/ml) 20.3 (16.-22.1) 18.9 (14.2-48.4) 52.4 (32.8-61.4) 0.198 0.198 0.198
Megalin (ng/ml) 12.9 (0.84-70.4) 1.5 (0-7.3) 18.9 (3.5-305.8) 0.293 0.293 0.293
Serum creatinine (umol/L) (67.3 ± 8.15) (64 ± 10.16) (73.8 ± 9.4) 0.372 0.372 0.372
Urea nitrogen (mmol/L) 3.1 (2.6-3.5) 4.9 (4.4-6.1) 4.7 (3.7-5.2) 0.006* 0.06 1
Uric acid (umol/L) 259 (214.7-362.5) 286 (244.2-339.7) 279 (243.2-411.5) 0.953 0.953 0.953
Total protein (gm/L) 73 (71.2-76) 71 (66.7-72.7) 72 (71-72) 0.237 0.237 0.237
Albumin (gm/L) 47 (44-47) 44 (41.5-46.7) 44 (43.2-45) 0.34 0.34 0.34
Cholesterol (mmol/L) 4.8 (4.1-5) 4.6 (3.7-5.2) 5.4 (4.4-6.4) 0.293 0.293 0.293
Triglyceride (mmol/L) 1.2 (0.6-1.3) 1.1 (0.95-1.4) 1.9 (0.93-2.6) 0.609 0.609 0.609
LDL (mmol/L) 2.5 (2.1-3) 2.8 (1.9-3.1) 3.9 (2.8-4.1) 0.13 0.13 0.13
HDL (mmol/L) 1.2 (1.1-1.7) 1.3 (1-1.4) 0.9 (0.9-1.2) 0.188 0.188 0.188
Homocysteine (umol/L) 8.5 (7.5-9.8) 9.1 (7.9-10.4) 7.9 (7.5-8.5) 0.743 0.743 0.743
Insulin (mcunit/mL) 8 (6.5-18.7) 11.8 (7.3-12.5) 9 (4.6-12.9) 0.833 0.833 0.833
C-peptide of insulin (ng/mL) 2.2 (1.5-3.1) 2.2 (1.7-2.6) 1.4 (1.3-2.1) 0.256 0.256 0.256
HbA1c % 5.1 (4.9-5.6) 7 (6.3-7.5) 7.8 (6.1-11.8) 0.016* 0.005* 1
Glucose (mmol/L) 4.8 (4.5-5.3) 7 (6.1-10) 7.2 (6.3-11.6) 0.011* 0.006* 1
BMI (Kg/m2) 25.7 (22.8-31.1) 28.1 (27.4-31.5) 31.9 (27.1-35.6) 0.237 0.237 0.237
Duration of DM (Years) - 4 (3-15) 3 (2.2-3.7) - - 0.237
Serum creatinine is the only parametric variable that is expressed as mean ± SD. While median and (interquartile range) are expressed for all the remaining non-
parametric variables.
eGFR, uVDBP, megalin, kidney profile tests (serum creatinine, urea nitrogen, uric acid), liver profile testes (total protein and albumin), lipid profile tests (cholesterol, 
triglyceride LDL, high-density lipoprotein [HDL]), homocysteine, insulin, c-peptide of insulin, HbA1c, glucose, BMI, and the duration of T2DM were compared among the 
three studied groups. 
* P-value ≤ 0.05 is considered as clinically significant.
Table 2: Shows the clinical characteristics of different variables for G1, G2 and G3 and the p-value between the groups.
Name of correlation Correlation Coefficient (r) P-value
eGFR and uVDBP -0.326 0.149
eGFR and megalin -0.315 0.165
Duration and megalin 0.143 0.642
Duration and uVDBP 0.054 0.861
uVDBP and megalin 0.001 0.998
Determined by Spearman correlation coefficient using Bivariate correlation analysis. 
Two-tailed P-value ≤ 0.05 is clinically significant.
Table 3: Shows the correlation coefficient and significance between eGFR, 
megalin, uVDBP and the duration of T2DM.
Figure 4: Shows a comparison between the studied groups with respect to 
eGFR.
(r=0.001, P=0.998). Furthermore, the duration of T2DM has non-
significant positive linear relationships between megalin (r=0.143, 
P=0.642) and eGFR (r=0.295, P=0.328) (Table 3).
Figure 5: Shows a comparison between the studied groups with respect to 
uVDBP.
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Comparison between the studied groups with respect to 
megalin
 Figure 6 demonstrates that megalin concentrations in G3 (18.9 
(3.5-305.8)) is non-significantly higher than G1 (12.9 (0.84-70.4), 
P=0.293) and G2 (1.5 (0-7.3), P=0.293). Moreover, there was no 
significant difference between G1 and G2 (P=0.293).
Comparison between the studied groups with respect to 
HbA1c
Figure 7 shows that Hb1Ac concentrations is increased in G3 (7.8 
(6.1-11.8)) significantly with G1 (5.1 (4.9-5.6), P=0.005) and non-
significantly with G2 (7 (6.3-7.5), P=1.00). In addition, G2 Hb1Ac 
concentrations is significantly higher than G1 (P=0.016).
Comparison between the studied groups with respect to 
glucose level
Figure 8 reveals that glucose level in G1 (4.8 (4.5-5.3) in significantly 
lower than G3 (7.2 (6.3-11.6), P=0.006) and G2 (7.2 (6.3-11.6), P=0.011). 
However, G3 and G2 show a non-significant high glucose level (P=1.00).
Comparison between the studied groups with respect to the 
duration of T2DM
Figure 9 demonstrates the duration of T2DM in G3 (3 (2.2-3.7)) and 
G2 (4 (3-15), in which G3 is non-significantly lower than G2 (P=0.237).
Comparison between the studied groups with kidney profile 
tests
The kidney profile tests of the measured serum creatinine, urea 
nitrogen and uric acid showed non-significant differences among 
the three groups. However, as shown in Figure 10 urea nitrogen 
concentration in G2 (4.9 (4.4-6.1)) is elevated significantly compared 
to G1 (3.1 (2.6-3.5), P=0.006) and non-significantly compared with G3 
(4.7 (3.7-5.2), P=1.00). However, the difference between G1 and G3 was 
non-significant (P=0.060).
Comparison between the studied groups with other variables
Lipids profile tests (cholesterol, triglyceride, LDL and HDL), 
liver profile tests (total protein and albumin), homocysteine, insulin, 
C-peptide of insulin and BMI were measured for all the three groups 
in which all of them shows non-significant differences among each 
other’s.
Figure 6:  Shows a comparison between the studied groups with respect to 
megalin.
Figure 7: Shows a comparison between the studied groups with respect to 
HbA1c.
Figure 8:  Shows a comparison between the studied groups with respect to 
glucose level.
Figure 9: Shows a comparison between the studied groups with respect to the 
duration of T2DM.
Figure 10:  Shows a comparison between the studied groups with respect to 
urea nitrogen test.
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Discussion
DM is a leading cause of mortality and morbidity that is a common 
disease in Qatar [1, 2]. T2DM is more common than T1DM, in which 
it occupies 90%-95% of the diabetic patients [3]. One of the most 
common complications of DM is DN [3]. DN is found in approximately 
30-40% of diabetic patients. It is described by low glomerular filtration 
rate (GFR) resulting in proteinuria. Also, it is a long-term complication 
that depends on the duration of diabetes [5]. DN is usually diagnosed 
according to the presence of albuminuria in urine. Moreover, eGFR 
is used to reveal the glomerular function and the kidney status. 
According to previous studies that were conducted in five different 
regions for uVDBP, it was hypothesized that patients with DN have 
higher concentrations of urinary VDBP and megalin than those who 
are healthy. Therefore, this research is aimed to study the uVDBP 
and megalin concentrations as biomarkers for DN in Qatari T2DM 
patients, where the study subjects (n=21) including males and females 
were divided into three groups based on their eGFR that indicates the 
progression of DN. G1; which is a healthy control group with normal 
eGFR ≥ 90 ml/min/1.73 m2, G2; which presents T2DM patients with 
normal eGFR ≥ 90 ml/min/1.73 m2 and G3; which is T2DM patients 
with abnormal eGFR <90 ml/min/1.73 m2. The significant differences 
among groups. It was observed that megalin and uVDBP concentration 
levels were non-significantly higher in G3 than G1 and G2. It also 
shows that the level of eGFR in G3 is significantly lower than those 
in G1 and G2 (P=0.005, P=0.004) respectively, while there was no 
Author/
Year/
Country
Title Study subjects and methodology Result(presented as mean ± SD) Conclusion
Fawzy and Abu 
AlSel (2018).
Saudi Arabia 
Assessment of vitamin D-binding 
protein and early prediction of 
nephropathy in type 2 Saudi 
diabetic patients
Study subjects: 160
-G1: 40 healthy volunteers.
120 T2DM patients:
-G2: normoalbuminuria.
-G3: microalbuminuria.
-G4: macroalbuminuria.
Methodology:
Quantitative sandwich ELISA
uVDBP levels were significantly 
elevated in G3 and G4 
individuals compared with those 
of the G1 and G2.
uVDBP levels (ng/mg):
G1 =(127.7 ± 21.9)
G2 =(193.1 ± 141.0)
G3 =(820.4 ± 402.8)
G4 =(1458.1 ± 210.0)
-uVDBP is a good marker for the 
early detection of renal disease in 
Saudi T2DM patients.
Khodeir et al. 
(2016)
Egypt 
Urinary level of vitamin D-binding 
protein as a new biomarker for 
diabetic nephropathy
Study subjects: 60
-G1:15 healthy people.
45 Patients with T2DM:
-G2: normoalbuminuric.
-G3: microalbuminuric.
-G4: Macroalbuminuric.
Methodology:
Quantitative sandwich ELISA
uVDBP levels were significantly 
elevated in G3 and G4 compared 
to G2 and G1.
uVDBP levels:
-G1=(16.400 ± 4.881)
-G2=(20.000 ± 5.720)
-G3=(247.267 ± 36.654)
-G4=(1449.333 ± 643.456)
-uVDBP levels are significantly 
increased in patients with DN.
-There is a strong positive correlation 
between the concentration of uVDBP 
and the development of DN.
-uVDBP levels are a potential 
biomarker for the early detection of 
DN in T2DM patients.
Shoukry, Bdeer 
Sel, and El-
Sokkary (2015).
New York
Urinary monocyte chemoattractant 
protein-1 and vitamin D-binding 
protein as biomarkers for early 
detection of diabetic
nephropathy in type 2 diabetes 
mellitus
Study subjects: 100
-G1: 25 healthy individuals.
75 T2DM patients:
-G2: 25 normo albuminuria.
-G3: 25 microalbuminuria.
-G4: 25 macroalbuminuria.
Methodology:
Quantitative sandwich ELISA
-uVDBP levels increased 
significantly in G3 and G4.
uVDBP/urinary creatinine levels 
(ng/mg):
G1=(123.4 ± 28.2)
G2=(472.5 ± 123.6)
G3=(984.3 ± 215.3)
G4=(1516.3 ± 228.6)
-uVDBP could be considered as 
novel diagnostic biomarker for 
diabetic nephropathy early detection.
Ali et al. (2015)
Baghdad
Estimation of urinary vitamin D 
binding protein as a biomarker 
in type 2 diabetic nephropathy 
and its correlation with estimated 
glomerular filtration rate
Study subjects: 90
-G1: 20 individuals (control group), 
apparently healthy with no diabetes 
and kidney diseases and with matched 
age and sex.
-G2: 40 T2DM Patients with normal 
eGFR (≥ 90 ml/min/1.73 m2).
-G3: 30 T2DM patients with abnormal 
eGFR
(˂ 90 ml/min/1.73 m2).
Methodology:
Quantitative sandwich ELISA
uVDBP levels (ng/ml):
G1=(250.5 ± 0.526)
G2=(350.63 ± 0.8)
G3=(503 ± 14.056)
The difference of uVDBP in 
all between all groups was 
significant.
eGFR (ml/min/1.73 m2):
G1=97.16 ± 1.177
G2=93.91 ± 1.834
G3=88.13 ± 1.543
The differences of eGFR in G1 
and G3, and G2 and G1 were 
significant.
-uVDBP levels in all the groups have 
significantly increased in patients 
with DN.
-There is a negative correlation 
between the elevated uVDBP levels 
and decreased eGFR.
-uVDBP levels are a novel predictor 
for the early detection of DN in 
T2DM patients.
Tian et al. (2013).
China
Elevated urinary level of vitamin 
D-binding protein as a novel 
biomarker for diabetic nephropathy
Study subjects: 150
-G1: 45 healthy volunteers.
105 diabetic patients:
-G2: 30 T2DM and 5 T1DM
with normoalbuminuria.
-G3: 30 T2DM and 5 T1DM
with microalbuminuria.
-G4: 28 T2DM and 7 T1DM
with macroalbuminuria.
Methodology:
Quantitative sandwich ELISA
uVDBP levels were significantly 
elevated in G3 and G4 
individuals compared with those 
of the G1 and G2.
uVDBP levels (ng/mg):
G1=(125.48 ± 98.27)
G2=(466.54 ± 213.63)
G3=(1,011.33 ± 325.30)
G4=(1,406.34 ± 239.66)
-Patients with DN have significantly 
elevated uVDBP levels.
-There is a strong positive correlation 
between the concentration of uVDBP 
and the development of DN.
-uVDBP levels are a potential 
indicator for the early detection and 
prevention of DN.
Table 4: Shows the previous studies of VDBP as a biomarker in DN.
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significant difference between G1 and G2, which is expected due to 
their classification. Moreover, the concentration of Hb1Ac and glucose 
level were significantly lower in G1 than G2 and G3 (P=0.016, P=0.005), 
(P=0.011, P=0.006) respectively, in which those tests used in diagnosing 
DM [11]. Additionally, comparing the duration of T2DM among G2 
and G3 did not show any significance. As mentioned previously, the 
progression of DN is affected by the duration [5], so it was expected 
to have significant longer duration of T2DM in G3 than G2, while 
it was shown that the duration of T2DM in G2 is non-significantly 
longer than G3. This could be due to the small sample size in which 
each group involve only seven individuals. Moving to the kidney profile 
tests, only the urea nitrogen test has shown a significant difference 
between groups. It shows that the concentration of urea nitrogen in G2 
is significantly higher than G1 (P=0.006) and no significant differences 
were found in G3 compared to G2 and G1. However, urea nitrogen 
values were in the normal range for all the groups. For G1 and G2 it 
was expected due to their normal eGFR values, but for G3 that has 
abnormal eGFR, it could be due to the minimal changes in the kidney 
structure and function that occurred at the early stages of kidney 
diseases [23], which mainly affects the eGFR in which urea nitrogen 
could not be affected yet. This also can explain the normal results of 
uric acid and serum creatinine. However, comparing serum creatinine 
with eGFR proofs the fact that increased serum creatinine will decrease 
eGFR [11]. Moreover, it showed no significant differences between the 
studied groups of lipid profile tests that include cholesterol, triglyceride, 
LDL and HDL as well as liver profiles, which include albumin and total 
protein. Furthermore, other tests containing homocysteine, insulin, 
C-peptide of insulin and BMI were measured for the three groups and 
all of them show non-significant differences. Furthermore, the values 
of those tests are within the normal reference ranges, except for HDL 
levels, which appear to be uniformly decreased in G3 compared to G1. 
Decreasing of HDL level in diabetic patients may associate with CKD. 
Triglyceride values vary in G3 in which some are normal and others are 
abnormal in which it usually increases in diabetic patients. However, 
normal triglyceride level could be referred to a controlled diet. In 
addition, measurements of serum albumin and total protein are proper 
tests of liver function because they measure the synthetic and metabolic 
pathways for these proteins [11]. Regarding insulin and C-peptide of 
insulin that shows normal ranges, most of the diabetic subjects were 
taking tablets to control the hyperglycemia that prevents or delay any 
of the complications. According to correlation analysis was used to 
figure out the association between different variables. These variables 
include eGFR, megalin, uVDBP and duration of T2DM. The results 
revealed that the correlation of eGFR with uVDBP and megalin was 
negatively weak with non-significant P-value. This proofs the fact that 
low eGFR result in proteinuria including increased secretion of VDBP 
and megalin [8]. Moreover, it was shown that the correlation between 
the duration of T2DM with uVDBP and megalin were positive with 
non-significant P-value. As mentioned previously, the progression of 
DN is influenced by the duration of the disease that leads to proteinuria 
[5]. Furthermore, it was indicated that the correlation between uVDBP 
with megalin was non-significantly positive. This explains the role 
of megalin in the endocytosis of uVDBP, where in DM patients, this 
process is damaged due to proteinuria and increased uVDBP secretions 
that result in PTECs injury and shedding of megalin in the urine [10]. 
Previous studies demonstrate that urinary VDBP and megalin are novel 
potential urinary biomarkers of DN in T2DM patients (Table 4 and 
Table 5). There were five different studies about uVDBP as a biomarker, 
where they were conducted in Saudi Arabia [7], Egypt [5], New York 
[27], Bagdad [26] and China. All of them indicated that uVDBP is 
considered as a potential biomarker that indicates the early stage of DN 
in T2DM patients. However Tian et al. [1] had a population of T2DM 
patients with few patients of T1DM. Furthermore it indicated that there 
is a strong positive correlation between the concentration of uVDBP 
and the development of DN. Moreover, demonstrated that there is a 
negative correlation between the elevated uVDBP levels and decreased 
eGFR. In addition, there was one study about megalin as a biomarker 
that was conducted in Japan by [30], which reveal that the urinary full-
length and ectodomain form of megalin are biomarkers that indicates 
the progression of DN in T2DM. The current study demonstrates that 
the urinary VDBP and megalin levels were non-significantly elevated 
in T2DM patients with DN. Moreover, a weak negative correlation was 
observed between eGFR with urinary VDBP and megalin levels [11].
Conclusion
In conclusion, DN is one of the most important complications in 
T2DM. Previous studies revealed that T2DM patients with nephropathy 
have higher concentrations of uVDBP that carries vitamin D to the 
target tissues, and megalin that mediates endocytosis in the proximal 
tubule than those who are healthy. The aim of the project is to study 
the urinary VDBP and megalin concentrations as biomarkers in 
Qatari T2DM patients with low eGFR that indicates the progression of 
nephropathy. Urinary VDBP and megalin were measured using ELISA. 
The study subjects were divided into three groups; group 1 (control 
group with eGFR ≥ 90 mL/min/1.73 m²), group 2 (T2DM patients 
with eGFR ≥ 90 mL/min/1.73 m²) and group 3; (T2DM patients with 
eGFR<90 mL/min/1.73 m²). This study reveals that urinary VDBP and 
megalin levels were non-significantly elevated in T2DM patients with 
DN. Moreover, a weak negative correlation was observed between the 
urinary VDBP and megalin levels with eGFR. However, it is suggested 
that these results could be due to some limitations. Further tests and 
experiments should be performed on larger sample size where the 
diabetic samples are from a diabetic clinic to confirm the association of 
megalin and VDBP in T2DM nephropathy.
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Significance of urinary full-
length and ectodomain forms 
of megalin in patients with 
type 2 diabetes.
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of megalin was elevated as 
DN progresses in T2DM.
Patients with normo-
albuminuria has significantly 
high urinary C-megalin levels 
than control group.
The presence of C-Megalin 
has a better correlation with 
low eGFR than albuminuria
Urinary full-length and 
ectodomain form of megalin are 
biomarkers that indicates the 
progression of DN in T2DM.
 
 
Table 5: Shows the previous study of megalin as a biomarker in DN.
Citation: Sharif E, Kitaz N, Hussain A, Alwakeel M (2019) Association of Urinary Vitamin D-binding Protein and Megalin as Biomarkers for Diabetic 
Nephropathy in Type 2 Diabetes Mellitus in Qatari Patients. J Diabetes Clin Prac 2: 109. 
Page 10 of 10
Volume 3   Issue 2 • 1000109J Diabetes Clin Prac, an open access journal
in the experimental work. Additionally, we would like to thanks Dr. Mahmoud 
Hassan for his help and guidance in the statistical analysis and Qatar Biobank 
for accepting the collaboration and provide us with the samples and the related 
clinical data. We are also grateful to our institution’s Qatar University Student Grant 
(QUST-1-CHS-2018-2), for funding our project.
Compliance with Ethical Standards
The experimental design including participation of human subjects were 
obtained from the Qatar Biobank (QBB), under the project no. Ex-2017-QBB-RES-
ACC-0082-0029.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contribution
Elham Sharif (corresponding author) designed and supervised the project. 
Naila Kitaz, Amal Hassan, Mariam Alwakeel contributed to data collection, data 
analysis, and manuscript draft. All authors contributed to the final editing and 
revision of the manuscript.
References
1. Tian XQ, Zhao LM, Ge JP, Zhang Y, Cheng Y, et al. (2014) Elevated urinary level 
of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp 
Ther Med 7: 411-416.
2. Zirie MA (2017) Diabetes on Qatar in Middle East Forum on Quality and Safety 
in Healthcare Hamad Medical Corporation.
3. Wu Y, Ding Y, Tanaka Y, Zhang W (2014) Risk factors contributing to type 2 
diabetes and recent advances in the treatment and prevention. Int J Med Sci 
11: 1185-200.
4. Awad SF, Flaherty M, Critchley J, Abu-Raddad LJ (2018) Forecasting the 
burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. 
Diabetes Res Clin Pract 137: 100-108.
5. Khodeir SA, Kotb NM, Okasha KM, Ahmed KA, Nagy HM, et al. (2016) Urinary 
level of vitamin D-binding protein as a new biomarker for diabetic nephropathy. 
Journal of The Egyptian Society of Nephrology and Transplantation 16: 32-38.
6. Denburg MR, Bhan I (2015) Vitamin D-Binding Protein in Health and Chronic 
Kidney Disease. Semin Dial 28: 636-644.
7. Fawzy MS, Abu BT, AlSel A (2018) Assessment of Vitamin D-Binding Protein 
and Early Prediction of Nephropathy in Type 2 Saudi Diabetic Patients. J 
Diabetes Res 1: 1-6.
8. Mirkovic K, Carolina RC, Wendy A, Hiddo JL,Maartje CJ, et al. (2013) 
Urinary vitamin D binding protein: a potential novel marker of renal interstitial 
inflammation and fibrosis. PLoS One 8: e55887.
9. Saito A, Sato H, Iino N, Takeda T (2010) Molecular mechanisms of receptor-
mediated endocytosis in the renal proximal tubular epithelium. J Biomed 
Biotechnol 103-272.
10. Christensen EI, Birn H, Storm T, Weyer K, Nielsen R (2012) Endocytic receptors 
in the renal proximal tubule. Physiology (Bethesda) 27: 223-36.
11. Bishop ML, Fody EP, Schoeff EF (2013) Clinical Chemistry: Principles, 
Techniques, Correlations. 7th edn.
12. Christos PJ, Chemaitelly H, Abu-Raddad LJ, Zirie MA, Dirk D (2014) Prevention 
of type II diabetes mellitus in Qatar: Who is at risk? Qatar Med J 2014: 70-81.
13. Jaam M, Mohamed Ibrahim MI, Kheir N, Hadi MA, Diab MI, et al. (2018) 
Assessing prevalence of and barriers to medication adherence in patients with 
uncontrolled diabetes attending primary healthcare clinics in Qatar. Prim Care 
Diabetes 12: 116-125.
14. Olokoba AB, Obateru OA, Olokoba LB (2012) Type 2 diabetes mellitus: a 
review of current trends. Oman Med J 27: 269-73.
15. Leighton E, Sainsbury CA, Jones GC (2017) A Practical Review of C-Peptide 
Testing in Diabetes. Diabetes Ther 8: 475-487.
16. Tangvarasittichai S (2015) Oxidative stress, insulin resistance, dyslipidemia 
and type 2 diabetes mellitus. World J Diabetes 6: 456-80.
17. Papadopoulou MN, Kanaka GC, Marketos N, Chrousos GP, Papassotiriou I 
(2017) Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab 
Sci 54: 326-342.
18. Dabla PK (2010) Renal function in diabetic nephropathy. World J Diabetes 1: 
48-56.
19. Zirie MA, MF, Yousef MF, Al-Mashaly A (2003) Complications of Diabetes 
Mellitus Among Patients Attending Outpatient Clinics in Qatar. Qatar Medical 
Journal 12: 129-132.
20. Bener A, Al-Laftah F, Al-Hamaq AO, Daghash M, Abdullatef WK et al. (2014) 
A study of diabetes complications in an endogamous population: an emerging 
public health burden. Diabetes Metab Syndr 8: 108-14.
21. Aldukhayel A (2017) Prevalence of diabetic nephropathy among Type 2 diabetic 
patients in some of the Arab countries. Int J Health Sci (Qassim) 11: 1-4.
22. Daehn IS (2018) Glomerular Endothelial Cells Stress and Cross-Talk With 
Podocytes in the Development of Diabetic Kidney Disease. Front Med 
(Lausanne) 5: 1-76.
23. Kumar Pasupulati A, Chitra PS, Reddy GB (2016) Advanced glycation end 
products mediated cellular and molecular events in the pathology of diabetic 
nephropathy. Biomol Concepts 7: 293-309.
24. Tuttle KR (2017) Back to the Future: Glomerular Hyperfiltration and the Diabetic 
Kidney. Diabetes. 66: 14-16.
25. Ravindran, S, Kuruvilla V, Wilbur K, Munusamy S (2017) Nephroprotective 
Effects of Metformin in Diabetic Nephropathy. J Cell Physiol 232: 731-742.
26. Ali ANM (2015) Estimation of Urinary Vitamin D Binding Protein as a Biomarker 
in Type 2 Diabetic Nephropathy and its correlation with estimated Glomerular 
Filtration Rate. Iraqi Journal of Community Medicine 28: 145-150.
27. Shoukry A, Bdeer Sel A, El-Sokkary RH (2015) Urinary monocyte 
chemoattractant protein-1 and vitamin D-binding protein as biomarkers for 
early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol Cell 
Biochem 408: 25-35.
28. De S, Kuwahara S, Saito A (2014) The endocytic receptor megalin and its 
associated proteins in proximal tubule epithelial cells. Membranes (Basel) 4: 
333-55.
29. Negri AL (2006) Proximal tubule endocytic apparatus as the specific renal 
uptake mechanism for vitamin D-binding protein/25-(OH)D3 complex. 
Nephrology (Carlton) 11: 510-515.
30. Ogasawara S, Hosojima M, Kaseda R, Kabasawa H, Yamamoto-Kabasawa K, 
et al. (2012) Significance of urinary full-length and ectodomain forms of megalin 
in patients with type 2 diabetes. Diabetes Care 35: 1112-8.
31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL et al. (2006) Using 
standardized serum creatinine values in the modification of diet in renal disease 
study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-54.
